17 December 2012
Details
Verdezyne, Inc.,
announced the sale of its proprietary
xylose isomerase technology,
enabling the metabolism of 5-carbon sugars,
to Dupont Industrial Biosciences.
Dupont has purchased rights to
Verdezyne's patented
xylose isomerase technology
covered by U.S. Patent for use in
the rapidly-commercializating
biofuels and biochemical fields.
The technology allows the fast and complete
utilization of biomass-sources C5 sugars
in production of various products of choice.
WWW.CHEMWINFO.COM BY KHUN PHICHAI
Benefit to Dupont
- Biomass bioprocessing is opening up
unique market opportunities
across a wide range of Dupont businesses and
the Verdezyne technology is a natural fit for
the Dupont's cellulosic portfolio.
- The addition of this leading xylose isomerase technology
further strengthens Dupont's leadership in
biomass derived sugar conversion to
biofuels and biochemicals.
About Verdezyne, Inc.
- A privately-held industrial biotechnology company
using proven and proprietary metabolic pathway
engineering tools to develop unique yeast strains for
cost-effective production of bio-based chemicals.
- Verdezyne's headoffice is in Carlsbad, CA, USA.
WWW.CHEMWINFO.COM BY KHUN PHICHAI
Verdezyne's products
1.Bio-based Dodecanedioic acid (DDDA)
Use : for the production of high performance Nylon 6,12
Input : low cost plant sourced oil feedstocks versus
butadiene for petroleum-based DDDA
Market opportunity : over US $ 250 million per year
2.Sebacic acid
Use : for the production of Nylon 6,10
Input : low cost plant sources oil feedstocks versus
caster oil of which supply is limited and
production creates highly poisonous Ricin
Market oppportunity : over US $ 600 million per year
3. Bio-based Adipic acid
Use : for the production of Nylon 6,6 and
thermoplastic polyurethanes
Market opportunity : US $ 6.3 billion per year
WWW.CHEMWINFO.COM BY KHUN PHICHAI
